Literature DB >> 26084418

The Misuse of Prescription Opioids: A Threat for Europe?

Jan van Amsterdam1, Wim van den Brink.   

Abstract

In the the past two decades the medical use of prescription opioids (POs), in particular oxycodone, increased up to 14-fold in the U.S. and Canada. The high consumption of these pain relievers also led to non-medical use and abuse of these substances which in turn resulted in a dramatic increase in the number of PO related fatalities and opioid dependent subjects. In the U.S. POs became the second most prevalent type of abused drug (4.5 million abusers; 1.7% of the population) after marijuana (8 million abusers) with currently 1.9 million (0.7% of the population) people dependent on opioid pain relievers. Pain relief was the leading motive for non-medical use in about 40% of the cases, but about half of non-medical PO users reported non-pain relief motives only, like to get high or to relax. Since 2011, there is a decline in the use and misuse of POs and reduction in painkiller overdose deaths in the U.S. probably due to the introduction of a variety of restrictive regulations. In Europe, the medical use of POs is increasing as well, but at a much slower rate than in the U.S. Moreover, in Europe non-medical use of POs and fatal PO incidents are (still) rare. The paper highlights and discusses the differences between Europe versus U.S. and Canada in an attempt to assess the risk of a PO abuse and overdose epidemic in Europe. It is concluded that the risk in Europe seems to be rather limited but vigilance is needed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26084418     DOI: 10.2174/187447370801150611184218

Source DB:  PubMed          Journal:  Curr Drug Abuse Rev        ISSN: 1874-4737


  45 in total

1.  Effective Canadian policy to reduce harms from prescription opioids: learning from past failures.

Authors:  Benedikt Fischer; Jürgen Rehm; Mark Tyndall
Journal:  CMAJ       Date:  2016-11-07       Impact factor: 8.262

2.  Medical use, non-medical use and use disorders of benzodiazepines and prescription opioids in adults: Differences by insurance status.

Authors:  Vítor Soares Tardelli; Thiago Marques Fidalgo; Julian Santaella; Silvia S Martins
Journal:  Drug Alcohol Depend       Date:  2019-09-21       Impact factor: 4.492

3.  Multimodal oral analgesia for non-severe trauma patients: evaluation of a triage-nurse directed protocol combining methoxyflurane, paracetamol and oxycodone.

Authors:  Damien Viglino; Nicolas Termoz Masson; Agnès Verdetti; Flore Champel; Cédric Falcon; Alexis Mouthon; Prudence Mabiala Makele; Roselyne Collomb Muret; Caroline Maindet Dominici; Maxime Maignan
Journal:  Intern Emerg Med       Date:  2019-07-09       Impact factor: 3.397

4.  The Contemporary American Drug Overdose Epidemic in International Perspective.

Authors:  Jessica Y Ho
Journal:  Popul Dev Rev       Date:  2019-02-20

5.  Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids.

Authors:  Abby Alpert; David Powell; Rosalie Liccardo Pacula
Journal:  Am Econ J Econ Policy       Date:  2018-11

6.  Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe.

Authors:  Karima Hider-Mlynarz; Philippe Cavalié; Patrick Maison
Journal:  Br J Clin Pharmacol       Date:  2018-04-02       Impact factor: 4.335

7.  Framing of the opioid problem in cancer pain management in Canada.

Authors:  R Asthana; S Goodall; J Lau; C Zimmermann; P L Diaz; A B Wan; E Chow; C De Angelis
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

8.  A cross-national analysis of the association between years of implementation of opioid substitution treatments and drug-related deaths in Europe from 1995 to 2013.

Authors:  Phillip L Marotta; Charlotte A McCullagh
Journal:  Eur J Epidemiol       Date:  2017-12-12       Impact factor: 8.082

9.  Opioid use in patients with rheumatoid arthritis 2005-2014: a population-based comparative study.

Authors:  Jorge A Zamora-Legoff; Sara J Achenbach; Cynthia S Crowson; Megan L Krause; John M Davis; Eric L Matteson
Journal:  Clin Rheumatol       Date:  2016-03-29       Impact factor: 2.980

Review 10.  Glial neuroimmune signaling in opioid reward.

Authors:  Hong Zhang; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Brain Res Bull       Date:  2019-11-29       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.